Gut
GLP1 agonists and liver outcomes in patients with T2DM and chronic liver disease
Among patients with chronic liver disease and type 2 diabetes, GLP1 agonists may result in lower risk of major adverse liver outcomes (MALO).
- Investigators used observational data from Swedish healthcare registers 2010 to 2020 to emulate a target trial of GLP1 agonists in patients with chronic liver disease and T2DM. An inverse-probability weighted marginal structural model was used to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, or MALO-related death) in initiators of GLP1 agonists vs. non-initiators.
- In intention-to-treat analysis, those who initiated GLP1 agonist therapy had a 10-year risk of MALO of 13.3% vs. 14.6% in non-initiators (risk ratio [RR], 0.91; 95% confidence interval [CI], 0.50-1.32). Corresponding 10-year per-protocol risk estimates were 7.4% and 14.4%, respectively (RR, 0.51; 95% CI, 0.14-0.88). Per-protocol risk estimates at 6 years were 5.4% vs. 9.0% (RR, 0.60; 95% CI, 0.29-0.90) and at 8 years were 7.2% vs. 11.7% (RR, 0.61; 95% CI, 0.21-1.01).
- The authors conclude that GLP1 agonists may be promising agents to reduce risk of chronic liver disease progression in patients with concurrent T2DM, although the findings need to be confirmed in randomized trials.
Source:
Wester A, et al. (2024, January 30). Gut. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/38253482/